Stealth BioTherapeutics Elamipretide: What You Need to Know

Stealth BioTherapeutics elamipretide is an investigational, mitochondria-targeted tetrapeptide being developed for rare mitochondrial diseases. Stealth BioTherapeutics is a clinical-stage biopharmaceutical company that has studied elamipretide for conditions like primary mitochondrial myopathy, Barth syndrome, and Leber hereditary optic neuropathy. Elamipretide is not FDA-approved for any indication in the United States.

What Is Elamipretide and How Does It Work?

Elamipretide is a synthetic peptide designed to concentrate inside mitochondria, the energy-producing structures within cells. The molecule consists of four amino acids: D-arginine, dimethyltyrosine, lysine, and phenylalanine. This short sequence allows it to cross cell membranes and accumulate in the inner mitochondrial membrane.

The elamipretide mechanism of action centers on cardiolipin, a phospholipid found in the inner mitochondrial membrane. By binding to cardiolipin, elamipretide helps stabilize the membrane, improves electron transport chain efficiency, and reduces reactive oxygen species. Researchers believe this may protect cells from energy failure in mitochondrial disorders.

Stealth BioTherapeutics: Company Background and Focus

Stealth BioTherapeutics is a biopharmaceutical company based in Newton, Massachusetts. The company focuses exclusively on mitochondrial dysfunction, a root cause of many rare and aging-related diseases. Stealth has advanced elamipretide into multiple clinical trials, often referred to as stealth elamipretide or elamipretide stealth biotherapeutics in research literature.

Unlike large pharmaceutical firms with broad portfolios, Stealth BioTherapeutics has centered its pipeline on elamipretide and a small number of follow-on compounds. This focused strategy reflects the high unmet need in mitochondrial medicine.

Elamipretide Clinical Trials and Potential Uses

Stealth BioTherapeutics has studied elamipretide for several serious conditions. The table below summarizes key clinical programs.

Indication	Phase	Status / Key Findings
Primary mitochondrial myopathy (PMM)	Phase 3 (MMPOWER-3)	Missed primary endpoint; some secondary measures favored elamipretide.
Barth syndrome	Phase 3 (TAZPOWER) / NDA	FDA issued a Complete Response Letter in 2022; additional data requested.
Leber hereditary optic neuropathy (LHON)	Phase 2	Early trials showed mixed results; further study needed.
Dry age-related macular degeneration	Phase 2	Ophthalmic formulation tested; results modest.
Heart failure / ischemia-reperfusion injury	Phase 1/2	Exploratory; no pivotal trials reported.

These programs show that Stealth BioTherapeutics has pursued elamipretide for both systemic and localized mitochondrial damage. However, no indication has received regulatory approval.

Elamipretide FDA Approval and Regulatory Status

As of this writing, elamipretide fda approval has not been granted for any condition. In 2022, the FDA declined to approve elamipretide for Barth syndrome, issuing a Complete Response Letter. The agency requested additional evidence of efficacy, leaving Stealth BioTherapeutics to design further trials.

The path to approval remains uncertain because mitochondrial diseases are rare and heterogeneous. Clinical trials must enroll small numbers of patients, making statistical significance difficult to achieve. Stealth BioTherapeutics continues to engage with the FDA on next steps.

Elamipretide Injection, Cost, and Availability

Elamipretide is not available as a pill or dietary supplement. The elamipretide injection is given subcutaneously or intravenously in clinical settings. Because the drug is investigational, patients cannot obtain it through standard prescriptions.

Many people search for elamipretide cost, but no commercial price exists yet. If approved, elamipretide would likely be priced as a rare disease therapy, which often costs hundreds of thousands of dollars per year. Expanded access programs may offer the drug to some patients outside of trials, but eligibility is limited.

It is important to distinguish elamipretide from an elamipretide supplement. Some online vendors sell "mitochondrial peptides" that claim to contain elamipretide, but these products are not FDA-approved and may be unsafe or ineffective. Always consult a healthcare professional before using any unapproved product.

Elamipretide vs. Common Mitochondrial Supplements

Many over-the-counter products claim to support mitochondrial health. Elamipretide is fundamentally different because it is a prescription-strength investigational drug, not a supplement. The table below compares elamipretide with popular mitochondrial supplements.

Product	Regulatory Status	Primary Mechanism	Typical Route
Elamipretide	Investigational drug (not FDA-approved)	Binds cardiolipin; stabilizes inner mitochondrial membrane	Subcutaneous or IV injection
Coenzyme Q10 (CoQ10)	Dietary supplement	Electron carrier in mitochondrial respiratory chain	Oral
MitoQ	Dietary supplement	Mitochondria-targeted antioxidant	Oral
Nicotinamide riboside (NR)	Dietary supplement	Boosts NAD+ levels	Oral

This comparison highlights that elamipretide works through a unique mechanism and requires medical administration. It is not an elamipretide supplement, and it should not be confused with oral mitochondrial support products.

Safety Considerations and Patient Guidance

In clinical trials, elamipretide has been generally well tolerated. Commonly reported side effects include injection site reactions, headache, dizziness, and fatigue. Long-term safety data are still limited because the drug remains investigational.

Anyone considering elamipretide should enroll in a clinical trial or an approved expanded access program. Self-treatment with research peptides is risky and not recommended. Patients with mitochondrial disease should work with a specialist to explore proven therapies and supportive care.

The Bottom Line on Stealth BioTherapeutics Elamipretide

Stealth BioTherapeutics elamipretide represents a targeted approach to mitochondrial dysfunction, but it is not yet a proven treatment. The company has completed multiple trials, yet FDA approval remains elusive. For now, elamipretide is available only through research settings, and patients should rely on their healthcare team for guidance.

COMMON QUESTIONS

Frequently Asked Questions

Is elamipretide FDA approved?

No, elamipretide is not FDA-approved for any indication in the United States. Stealth BioTherapeutics received a Complete Response Letter from the FDA in 2022 for its Barth syndrome application, and the company is conducting additional trials.

What is elamipretide used for?

Elamipretide is being investigated for rare mitochondrial diseases such as primary mitochondrial myopathy, Barth syndrome, and Leber hereditary optic neuropathy. It is also being studied in dry age-related macular degeneration and heart conditions, but none of these uses are approved yet.

Can I buy elamipretide as a supplement?

No, elamipretide is an investigational prescription drug, not a dietary supplement. Products sold online as 'elamipretide supplements' are not FDA-approved and should be avoided because their safety and effectiveness are unknown.